Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction Learning

Not Applicable

• Conditions: F40.1; F40.2; F40.00; F40.01; F41.0; Social phobias; Specific (isolated) phobias; Panic disorder [episodic paroxysmal anxiety]

• Registration Number: DRKS00008743
• Lead Sponsor: Technische Universität Dresden,Institut für Klinische Psychologie und Psychotherapie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-06-18
• Study Completion: 2019-07-24
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 726

Inclusion Criteria

• age 15 – 70 years
• on or more of the following DSM-V Anxiety Disorders: Panic disorder, Agoraphobia, Social Anxiety Disorder, Specific Phobia
• HAMA – Score = 18
• CGI – Score = 3
• Can attend Therapie regularly (with or without suppot)
• Informed Consent

Exclusion Criteria

• Every reason the protocol may not be upheld (e.g. planned hospitalization within study time frame, planning to move away, etc.)
• Current Suicidal tendency
• DSM-V Bipolar Disorder
• DSM-V Psychotic Disorder
• DSM-V Borderline PD
• Current treatment of other Mental Disorder (Drugs, Psychotherapy)
• Current Alcohol, Benzodiazepine or other Substance Use Disorders
• Severe medical illness/condition (every serious physical illness, including cardiovascular, kidney, endocrinological and neurological conditions, Hepatitis or other clinical findings that suggest a severe illness and may affect participation in the study)

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Stronger reduction of anxiety symptoms in the IPI group than in the TAU group, Anxiety symptoms are assessed using the HAM-A at Baseline, Post/after session twelve and Follow up/after six months

Secondary Outcome Measures

Name	Time	Method
CGI (symptom severity),<br>CIDI (DIA-X) (categorical diagnosis),<br>DSM-5 Cross-D(anxiety),<br>BSI (SCL-90) (psychopathol. symptoms),<br>BDI-II (depressive symptoms),<br>ASI (anxiety sensitivity),<br>PAS (panic/agoraphobia),<br>ACQ (cognition in agoraphobia)<br>BSQ (bodily anxiety/cognition/avoidance)<br>MI (agoraphobic avoidance),<br>GAD-7 (worrying),<br>LSAS (social anxiety),<br>DSM-5 Specific Phobia Scale<br>WHODAS 2.0 (disability),<br>EQ5D (quality of life),<br>All measurements are taken three times (Baseline, Post/after session twelve, Follow up/after six months), the BSI additionally during course of treatment